Table S5 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Table S5. Nonsynonymous single nucleotide variants (SNVs) and insertions/deletions (indels) identified by whole exome sequencing (WES) and/or initial panel sequencing. Each sheet is a different tumor sample.

补充表S5：通过全外显子组测序（whole exome sequencing, WES）和/或初始靶向测序面板鉴定得到的错义单核苷酸变异（Nonsynonymous single nucleotide variants, SNVs）与插入缺失（insertions/deletions, indels）。每个工作表对应一个不同的肿瘤样本。